CVRx, Inc. (NASDAQ:CVRX) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its holdings in shares of CVRx, Inc. (NASDAQ:CVRX) by 10,520.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 628,286 shares of the company’s stock after purchasing an additional 622,370 shares during the quarter. JPMorgan Chase & Co. owned 2.59% of CVRx worth $7,960,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in CVRX. Barclays PLC grew its stake in CVRx by 312.5% in the third quarter. Barclays PLC now owns 19,067 shares of the company’s stock worth $169,000 after purchasing an additional 14,445 shares in the last quarter. Jane Street Group LLC lifted its holdings in CVRx by 36.1% during the 3rd quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock worth $168,000 after buying an additional 5,053 shares during the last quarter. Geode Capital Management LLC grew its position in shares of CVRx by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 295,124 shares of the company’s stock worth $2,600,000 after acquiring an additional 6,443 shares in the last quarter. State Street Corp grew its position in shares of CVRx by 11.4% in the 3rd quarter. State Street Corp now owns 264,733 shares of the company’s stock worth $2,332,000 after acquiring an additional 27,071 shares in the last quarter. Finally, Calamos Advisors LLC acquired a new stake in shares of CVRx during the 4th quarter valued at approximately $134,000. 75.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on CVRX. Craig Hallum lifted their price objective on shares of CVRx from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Canaccord Genuity Group decreased their price target on shares of CVRx from $23.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, April 8th. Piper Sandler increased their price objective on shares of CVRx from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 5th. Lake Street Capital decreased their target price on CVRx from $19.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, April 8th. Finally, William Blair upgraded CVRx from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.83.

CVRx Stock Performance

CVRX opened at $6.15 on Thursday. The company has a current ratio of 12.06, a quick ratio of 10.23 and a debt-to-equity ratio of 0.69. The business’s 50 day moving average is $11.69 and its 200-day moving average is $12.78. The stock has a market cap of $160.12 million, a PE ratio of -2.29 and a beta of 1.34. CVRx, Inc. has a twelve month low of $5.87 and a twelve month high of $18.55.

CVRx (NASDAQ:CVRX) last announced its earnings results on Tuesday, February 4th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.06). CVRx had a negative net margin of 116.91% and a negative return on equity of 93.06%. On average, analysts predict that CVRx, Inc. will post -1.91 earnings per share for the current year.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.